|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o AIDS Healthcare Foundation in Los Angeles, along with an international coalition of AIDS groups, launched a campaign urging F. Hoffmann-La Roche Ltd., of Basel, Switzerland, to lower the price of the drug Fuzeon. The U.S. advocates wrote a letter to Roche saying, "Fuzeon's $20,000 price tag is out of the price range for most AIDS patients," and that it "threatens to bankrupt already financially stressed Medicaid and AIDS drug-resistance programs." Fuzeon, a fusion inhibitor for HIV-1, developed in partnership with Trimeris Inc., of Durham, N.C., was approved in March. (See BioWorld Today, March 17, 2003.)
o Ansata Therapeutics Inc., of San Diego, received ...